InterVenn Biosciences

InterVenn is a life-science company unlocking the value of glycoproteomics — the study of glycosylated proteins, which are responsible for driving protein function — for the development of transformational healthcare solutions.

By pairing high-throughput mass spectrometry with AI and machine learning, InterVenn’s platform reads signals in the glycome that conventional approaches miss. From that foundation it can produce a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and, potentially, therapeutics.

The company brought together an unusual combination of expertise — from Nobel-laureate glycobiology to large-scale machine learning — to move early cancer detection out of the research lab and toward the clinic, raising more than $200M across its rounds to do it.